Meta⁃analysis of efficacy and safety of Dachengqi Decoction combined with octreotide and conventional therapy for early postoperative inflammatory small bowel obstruction

ZHOU Mi; WANG Dongjun; GUAN Yuanyuan; TIAN Zhikui; SUN Xuan; WANG Hongwu

doi:10.16305/j.1007-1334.2023.2208023

您当前的位置：

首页 >

文章列表页 >

Meta⁃analysis of efficacy and safety of Dachengqi Decoction combined with octreotide and conventional therapy for early postoperative inflammatory small bowel obstruction

更新时间：2023-01-07

- Meta⁃analysis of efficacy and safety of Dachengqi Decoction combined with octreotide and conventional therapy for early postoperative inflammatory small bowel obstruction
- Shanghai Journal of Traditional Chinese Medicine Vol. 57, Issue 1, Pages: 39-45(2023)
- 作者机构：
  
  1.天津中医药大学公共卫生与健康科学学院（天津 301617）
- 作者简介：
- 基金信息：
- DOI：10.16305/j.1007-1334.2023.2208023
  CLC：
扫描看全文
周密,王东军,关媛媛,等.大承气汤联合奥曲肽及常规疗法治疗术后早期炎性肠梗阻疗效及安全性的Meta分析[J].上海中医药杂志,2023,57(1):39-45.

ZHOU Mi,WANG Dongjun,GUAN Yuanyuan,et al.Meta⁃analysis of efficacy and safety of Dachengqi Decoction combined with octreotide and conventional therapy for early postoperative inflammatory small bowel obstruction[J].Shanghai Journal of Traditional Chinese Medicine,2023,57(1):39-45.
周密,王东军,关媛媛,等.大承气汤联合奥曲肽及常规疗法治疗术后早期炎性肠梗阻疗效及安全性的Meta分析[J].上海中医药杂志,2023,57(1):39-45. DOI： 10.16305/j.1007-1334.2023.2208023.

ZHOU Mi,WANG Dongjun,GUAN Yuanyuan,et al.Meta⁃analysis of efficacy and safety of Dachengqi Decoction combined with octreotide and conventional therapy for early postoperative inflammatory small bowel obstruction[J].Shanghai Journal of Traditional Chinese Medicine,2023,57(1):39-45. DOI： 10.16305/j.1007-1334.2023.2208023.

摘要

目的,2,系统评价大承气汤联合奥曲肽及常规疗法治疗术后早期炎性肠梗阻（EPISBO）的有效性和安全性。,方法,2,计算机检索PubMed、中国知网（CNKI）、万方数据知识服务平台（WanFang Data）、维普中文期刊服务平台（VIP）等数据库，收集以奥曲肽联合常规疗法为对照，观察大承气汤联合奥曲肽及常规疗法治疗EPISBO有效性及安全性的临床随机对照试验文献，文献发表时间为建库至2022年8月5日。采用Cochrane系统评价手册评价纳入文献的方法学质量，提取相关数据，借助RevMan5.4软件对数据进行Meta分析。,结果,2,共纳入6篇文献，涉及病例624例。Meta分析结果显示，大承气汤联合奥曲肽及常规疗法治疗EPISBO的总有效率高于奥曲肽联合常规疗法［,OR,=7.16，95%,CI,（3.32，15.44）］，且能更好地缓解腹痛腹胀［,MD,=-1.81，95%,CI,（-2.71，-0.92）］，促进肛门排气［,MD,=-0.95，95%,CI,（-1.21，-0.69）］及排便［,MD=,-0.62，95%,CI,（-0.95， -0.29）］，缩短症状消失时间［,MD,=-1.55，95%,CI,（-2.70，-0.40）］，差异有统计学意义（,P,<,0.01）。与奥曲肽联合常规疗法相比，在降低肿瘤坏死因子-α（TNF-α）［,MD,=-3.87，95%,CI,（-8.32，0.58）］、超敏C反应蛋白（hs-CRP）［,MD,=-4.11，95%,CI,（-8.90，0.69）］、白介素-6（IL-6）［,MD,=-41.86，95%,CI,（-107.38，23.65）］水平以及不良反应发生率［,MD,=0.91，95%,CI,（0.40，2.07）］方面，大承气汤联合奥曲肽及常规疗法未见明显优势（,P,>,0.05）。,结论,2,大承气汤联合奥曲肽及常规疗法治疗EPISBO疗效较好，但由于纳入的文献数量较少、质量较低，所得结论仍需更高质量的研究加以论证。

Abstract

Objective,2,To systematically evaluate the efficacy and safety of Dachengqi Decoction （DCQD） combined with octreotide and conventional therapy in the treatment of early postoperative inflammatory small bowel obstruction （EPISBO）.,Methods,2,Clinical randomized controlled trials （RCTs） that observed the effectiveness and safety of DCQD plus octreotide and conventional therapy in treating EPISBO with octreotide plus conventional therapy as the control were retrieved by searching the following databases as China National Knowledge Infrastructure （CNKI）， Wanfang Data Knowledge Service Platform （WanFang Data） and VIP Chinese Journal Service Platform （VIP）， etc. The collected RCTs were published between the dates of database establishment and August 5， 2022. The Cochrane systematic review manual was used to evaluate the methodological quality of the included RCTs and extract relevant data， and RevMan 5.4 was used to perform a meta-analysis of the extracted data.,Results,2,The included 6 articles involved 624 cases. The meta-analysis showed that the total effective rate of DCQD plus octreotide and conventional therapy for EPISBO was higher than that of octreotide plus conventional therapy ［,OR,=7.16，95%,CI,=（3.32，15.44）］， and DCQD plus octreotide and conventional therapy could better relieve abdominal pain and bloating ［,MD,=-1.81，95%,CI,=（-2.71，-0.92）］， facilitate anal gas evacuation ［,MD,=-0.95，95%,CI,=（-1.21， -0.69）］ and defecation ［,MD,=-0.62，95%,CI,=（-0.95，-0.29）］， and shorten the time course of symptom disappearance ［,MD,=-1.55，95%,CI,=（-2.70， -0.40）］， with a statistically significant difference （,P,<,0.01）. DCQD plus octreotide and conventional therapy had no significant advantage in lowering levels of tumor necrosis factor-α （TNF-α）［,MD,=-3.87，95% ,CI,=（-8.32，0.58）］， hypersensitive C-reactive protein （hs-CRP）［,MD,=-4.11，95% ,CI,=（-8.90，0.69）］， interleukin-6 （IL-6）［,MD,=-41.86，95%,CI,=（-107.38，23.65）］， and the incidence of adverse reactions ［,MD,=0.91， 95%,CI,=（0.40，2.07）］（,P,>,0.05）.,Conclusion,2,DCQD plus octreotide and conventional therapy has quite good efficacy in the treatment of EPISBO， but the conclusion needs to be validated by studies of higher quality due to the low quantity and quality of included literature.

关键词

术后早期炎性肠梗阻大承气汤奥曲肽临床疗效Meta分析

Keywords

early postoperative inflammatory small bowel obstructionDachengqi Decoctionoctreotideclinical efficacymeta-analysis

references

白江江，宗新玲，高维东，等. 结直肠癌术后早期炎性肠梗阻的诊断和治疗［J］. 中国现代医学杂志，2020， 30（10）： 67-70．

赵琳琳. 术后早期炎性肠梗阻的治疗进展［J］. 青海医药杂志，2018， 48（4）： 79-80．

PETERS E G， DE JONGE W J， SMEETS B J， et al. The contribution of mast cells to postoperative ileus in experimental and clinical studies［J］. Neurogastroenterol Motil， 2015， 27（6）： 743-749．

朱维铭，李宁，黎介寿，等. 术后早期炎性肠梗阻的治疗［J］. 中国实用外科杂志，2002， 22（4）： 29-30．

赵洪飞，胡仕祥. 通腑活血汤治疗术后早期炎性肠梗阻的疗效观察［J］. 中国中医急症，2019， 28（12）： 2206-2208．

阿不都外力·赛买提，依力哈木·买买提，肖开提·依不拉音，等. 血必净注射液辅助治疗对腹部术后炎性肠梗阻血清炎性因子水平的影响［J］. 陕西中医，2017， 38（11）： 1493-1494.

张宸宇，夏长军. 基于数据挖掘的中药治疗术后早期炎性肠梗阻用药规律分析［J］. 中药药理与临床，2020， 36（6）： 202-205.

邵华，卢国军，傅旭堂. 奥曲肽联合复方大承气汤治疗术后早期炎性肠梗阻的疗效观察［J］.中国中西医结合消化杂志，2014， 22（11）： 690-691.

史志涛，刘洁，孟源，等. 复方大承气汤对术后早期炎性肠梗阻的疗效观察［J］. 中国临床医生，2014， 42（6）： 52-54.

王军，张文胜，裴效瑞，等. 大承气汤联合奥曲肽治疗术后早期炎性肠梗阻疗效和安全性分析［J］. 辽宁中医杂志，2019， 46（3）： 567-570.

张军，谢秀平. 常规西药联合大承气汤化裁对于上消化道穿孔术后早期炎性肠梗阻患者hs-CRP、TNF-α及IL-6的影响［J］. 现代中西医结合杂志，2017， 26（22）： 2443-2445.

张文理. 大承气汤联合奥曲肽治疗术后早期炎性肠梗阻的临床效果［J］. 内蒙古中医药，2021， 40（4）： 52-54.

张晓庆，张宏文，郝玉杰，等. 常规西药联合大承气汤化裁对于上消化道穿孔术后早期炎性肠梗阻患者hs-CRP，TNF-α及IL-6的影响［J］. 养生保健指南，2021（37）： 68-69.

张艳，张宸宇，夏长军，等. 基于TLR4/Myd88/NF-κB通路探讨大黄牡丹汤对术后早期炎性肠梗阻大鼠的干预机制［J］. 中药药理与临床，2021， 37（6）： 2-7.

刘莹，甄文剑，王雅琼. 增液承气汤加减保留灌肠佐治术后粘连性肠梗阻（气滞血瘀证）的疗效观察［J］. 中国中医急症，2016， 25（8）： 1626-1628.

李文，郑芳，张集圣. 大承气汤对急性细菌性腹膜炎家兔重要脏器血流的影响［J］. 中国中西医结合外科杂志，1999， 5（2）： 114-116．

郑香琴，冯惠春，郑晓真，等. 浓煎大承气汤在老年癌性不全肠梗阻中的应用［J］. 新中医，2021， 53（9）： 102-106.

侯晓圆，何煜宇. 术后早期炎性肠梗阻的中医治疗研究进展［J］. 西部中医药，2013， 26（4）： 127-129.

江守军，王雪利，陈玉. 音频电理疗联合奥曲肽治疗术后早期炎性肠梗阻22例［J］. 现代中西医结合杂志，2011， 20（3）： 339-340.

许慕明，庄业忠，王伟峰，等. 奥曲肽在肠梗阻治疗中的作用［J］. 西部医学，2009， 21（7）： 1171-1173.

Views

182

下载量

CSCD

CNKI被引量

Alert me when the article has been cited

提交

Tools

Publicity Resources

Meta-analysis on efficacy and safety of Ginkgo Folium extract in treating diabetic kidney disease

Meta-analysis on Sofren Injection in treatment of heart failure

Research progress in anti⁃tumor clinical efficacy and mechanism of action of Sarcandrae Herba

Meta⁃analysis of clinical efficacy of Xuefu Zhuyu Decoction for post⁃stroke depression

Meta⁃analysis of clinical efficacy of Chinese herbal formulas on obesity based on randomized controlled trials

Related Author

No data

Related Institution

The Second Clinical Medical College of Henan University of Chinese Medicine

Department of Nephropathy， Henan Province Hospital of Traditional Chinese Medicine， The Second Hospital Affiliated to Henan University of Chinese Medicine

Department of Pharmacy, Guangdong Second Traditional Chinese Medicine Hospital

Sichuan Institute for Translational Chinese Medicine

Shanghai University of Traditional Chinese Medicine

⁰